(QURE) Uniqure - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.087m USD | Total Return: 90.5% in 12m

Gene Therapies, Rare Disease Treatments, Biopharmaceuticals
Total Rating 27
Safety 30
Buy Signal -1.30
Biotechnology
Industry Rotation: +6.6
Market Cap: 1.09B
Avg Turnover: 25.1M USD
ATR: 9.52%
Peers RS (IBD): 10.8
Risk 5d forecast
Volatility177%
Rel. Tail Risk-42.4%
Reward TTM
Sharpe Ratio0.94
Alpha2.34
Character TTM
Beta2.277
Beta Downside2.917
Drawdowns 3y
Max DD87.21%
CAGR/Max DD-0.06
EPS (Earnings per Share) EPS (Earnings per Share) of QURE over the last years for every Quarter: "2021-03": -0.91, "2021-06": 8.51, "2021-09": -0.79, "2021-12": 0.17, "2022-03": -1, "2022-06": -0.84, "2022-09": -1.02, "2022-12": 0.15, "2023-03": -1.63, "2023-06": -1.44, "2023-09": -1.88, "2023-12": -1.53, "2024-03": -1.36, "2024-06": -1.16, "2024-09": -0.91, "2024-12": -1.4415, "2025-03": -0.7278, "2025-06": -0.69, "2025-09": -1.38, "2025-12": -0.4739, "2026-03": 0,
EPS CAGR: 15.76%
EPS Trend: 23.1%
Last SUE: 2.07
Qual. Beats: 2
Revenue Revenue of QURE over the last years for every Quarter: 2021-03: 0.454, 2021-06: 463.868, 2021-09: 1.989, 2021-12: 57.691, 2022-03: 1.792, 2022-06: 0.497, 2022-09: 1.449, 2022-12: 102.745, 2023-03: 5.325, 2023-06: 2.422, 2023-09: 1.407, 2023-12: 6.689, 2024-03: 8.485, 2024-06: 11.126, 2024-09: 2.287, 2024-12: 5.221, 2025-03: 1.567, 2025-06: 5.262, 2025-09: 3.701, 2025-12: 5.568, 2026-03: null,
Rev. CAGR: 35.30%
Rev. Trend: 15.1%
Last SUE: 0.47
Qual. Beats: 0

Warnings

Share dilution 17.7% YoY - potential capital distress

Interest Coverage Ratio -2.5 is critical

Altman Z'' -4.38 < 1.0 - financial distress zone

Volatile

Tailwinds

No distinct edge detected

Description: QURE Uniqure

uniQure N.V. (QURE) is a biotechnology company specializing in the development of gene therapies for rare and devastating diseases. Its commercial portfolio includes HEMGENIX, a treatment for hemophilia B, while its clinical pipeline focuses on central nervous system and metabolic disorders. The companys lead candidate, AMT-130, is currently in Phase I/II trials for Huntington’s disease, alongside several early-stage programs for epilepsy, ALS, and Fabry disease.

The gene therapy sector operates under a high-intensity R&D model where companies utilize viral vectors to deliver functional genes into a patients cells to treat the underlying cause of genetic conditions. Unlike traditional pharmaceuticals that require chronic dosing, gene therapies are often designed as one-time curative treatments, which commands a premium pricing structure and specialized manufacturing requirements.

Strategic partnerships are central to the business model; uniQure maintains licensing and supply agreements with CSL Behring and Apic Bio to facilitate global commercialization and production. For a deeper analysis of these clinical milestones and valuation metrics, consult ValueRay. The company remains headquartered in Amsterdam, focusing on advancing its proprietary technology platform through rigorous clinical study phases.

Headlines to Watch Out For
  • Hemgenix royalty and milestone payments from CSL Behring drive immediate revenue growth
  • Clinical data readouts for AMT-130 determine long-term valuation in Huntington’s disease
  • Pipeline expansion into epilepsy and ALS increases R&D expenditure and capital requirements
  • Regulatory approval timelines for gene therapy candidates impact future market exclusivity
  • High cash burn rates necessitate strategic partnerships or dilutive secondary equity offerings
Piotroski VR‑10 (Strict) 1.0
Net Income: -199.0m TTM > 0 and > 6% of Revenue
FCF/TA: -0.22 > 0.02 and ΔFCF/TA 13.36 > 1.0
NWC/Revenue: 3.68k% < 20% (prev 1.29k%; Δ 2.39k% < -1%)
CFO/TA -0.22 > 3% & CFO -178.0m > Net Income -199.0m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 10.43 > 1.5 & < 3
Outstanding Shares: last quarter (57.5m) vs 12m ago 17.73% < -2%
Gross Margin: 71.08% > 18% (prev 0.32%; Δ 7.08k% > 0.5%)
Asset Turnover: 2.33% > 50% (prev 4.87%; Δ -2.54% > 0%)
Interest Coverage Ratio: -2.53 > 6 (EBITDA TTM -142.3m / Interest Expense TTM 62.0m)
Altman Z'' -4.38
A: 0.72 (Total Current Assets 656.0m - Total Current Liabilities 62.9m) / Total Assets 824.9m
B: -1.61 (Retained Earnings -1.33b / Total Assets 824.9m)
C: -0.23 (EBIT TTM -157.1m / Avg Total Assets 690.7m)
D: -2.21 (Book Value of Equity -1.38b / Total Liabilities 626.0m)
Altman-Z'' Score: -4.38 = D
Beneish M -1.77
DSRI: 3.71 (Receivables 12.9m/5.88m, Revenue 16.1m/27.1m)
GMI: 0.46 (GM 71.08% / 32.42%)
AQI: 0.73 (AQ_t 0.17 / AQ_t-1 0.24)
SGI: 0.59 (Revenue 16.1m / 27.1m)
TATA: -0.03 (NI -199.0m - CFO -178.0m) / TA 824.9m)
Beneish M-Score: -1.77 (Cap -4..+1) = CCC
What is the price of QURE shares? As of April 09, 2026, the stock is trading at USD 15.89 with a total of 1,431,951 shares traded.
Over the past week, the price has changed by -5.92%, over one month by -11.67%, over three months by -31.36% and over the past year by +90.53%.
Is QURE a buy, sell or hold? Uniqure has received a consensus analysts rating of 4.54. Therefore, it is recommended to buy QURE.
  • StrongBuy: 9
  • Buy: 2
  • Hold: 2
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the QURE price?
Analysts Target Price 37.8 137.7%
Uniqure (QURE) - Fundamental Data Overview as of 08 April 2026
P/E Forward = 27.933
P/S = 67.5479
P/B = 5.3884
Revenue TTM = 16.1m USD
EBIT TTM = -157.1m USD
EBITDA TTM = -142.3m USD
Long Term Debt = 49.7m USD (from longTermDebt, last quarter)
Short Term Debt = 3.86m USD (from shortTermDebt, last quarter)
Debt = 536.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -85.9m USD (recalculated: Debt 536.6m - CCE 622.5m)
Enterprise Value = 1.00b USD (1.09b + Debt 536.6m - CCE 622.5m)
Interest Coverage Ratio = -2.53 (Ebit TTM -157.1m / Interest Expense TTM 62.0m)
EV/FCF = -5.63x (Enterprise Value 1.00b / FCF TTM -178.0m)
FCF Yield = -17.77% (FCF TTM -178.0m / Enterprise Value 1.00b)
 FCF Margin = -1.11k% (FCF TTM -178.0m / Revenue TTM 16.1m)
 Net Margin = -1.24k% (Net Income TTM -199.0m / Revenue TTM 16.1m)
 Gross Margin = 71.08% ((Revenue TTM 16.1m - Cost of Revenue TTM 4.66m) / Revenue TTM)
Gross Margin QoQ = 38.85% (prev 89.25%)
Tobins Q-Ratio = 1.21 (Enterprise Value 1.00b / Total Assets 824.9m)
Interest Expense / Debt = 2.72% (Interest Expense 14.6m / Debt 536.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = -124.1m (EBIT -157.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.43 (Total Current Assets 656.0m / Total Current Liabilities 62.9m)
Debt / Equity = 2.70 (Debt 536.6m / totalStockholderEquity, last quarter 198.9m)
 Debt / EBITDA = 0.60 (negative EBITDA) (Net Debt -85.9m / EBITDA -142.3m)
 Debt / FCF = 0.48 (negative FCF - burning cash) (Net Debt -85.9m / FCF TTM -178.0m)
 Total Stockholder Equity = 114.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -28.81% (Net Income -199.0m / Total Assets 824.9m)
RoE = -174.0% (Net Income TTM -199.0m / Total Stockholder Equity 114.3m)
RoCE = -95.76% (EBIT -157.1m / Capital Employed (Equity 114.3m + L.T.Debt 49.7m))
 RoIC = -74.94% (negative operating profit) (NOPAT -124.1m / Invested Capital 165.6m)
 WACC = 10.08% (E(1.09b)/V(1.62b) * Re(13.99%) + D(536.6m)/V(1.62b) * Rd(2.72%) * (1-Tc(0.21)))
Discount Rate = 13.99% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 9.64%
 [DCF] Fair Price = unknown (Cash Flow -178.0m)
 EPS Correlation: 23.10 | EPS CAGR: 15.76% | SUE: 2.07 | # QB: 2
Revenue Correlation: 15.07 | Revenue CAGR: 35.30% | SUE: 0.47 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.76 | Chg7d=-0.003 | Chg30d=+0.051 | Revisions Net=-2 | Analysts=9
EPS current Year (2026-12-31): EPS=-2.97 | Chg7d=-0.004 | Chg30d=-0.222 | Revisions Net=-3 | Growth EPS=-1.5% | Growth Revenue=+115.2%
EPS next Year (2027-12-31): EPS=-2.33 | Chg7d=-0.058 | Chg30d=-1.380 | Revisions Net=-5 | Growth EPS=+21.6% | Growth Revenue=+206.5%
[Analyst] Revisions Ratio: -0.33 (2 Up / 4 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle